Sign In
Buy GMAB
$28.87
+0.230 (+0.80%)
At Close: Jul 31, 2026
Avidity Partners Management LP Cuts Stock Holdings in Genmab A/S Sponsored ADR $GMAB
03:49am, Saturday, 01'st Aug 2026
Avidity Partners Management LP reduced its stake in Genmab A/S Sponsored ADR (NASDAQ: GMAB) by 45.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the
Genmab's H1 Preview: Darzalex Beats The Sales Outlook
02:38am, Tuesday, 28'th Jul 2026
Genmab's buy rating with a $36 12-month target implies roughly 25% upside from the $28.74 reference price. DARZALEX H1 sales reached $8.17B, already exceeding half of Genmab's $16.0B full-year assumpt
COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today provided clarification on the primary endpoints from the Phase 3 EPCORE® DLBCL-1 st
Genmab: Multiple Late-Stage Readouts Ahead
11:34am, Wednesday, 22'nd Jul 2026
Genmab has underperformed so far this year despite strong commercial performance and largely positive pipeline news flow. Strong Q2 royalty product sales (Darzalex +18% Y/Y, Tecvayli +57% Y/Y) support
Wall Street lit up Tuesday with massive earnings beats and a crypto surge, but Wednesday morning futures are already flashing red. Find out which stocks analysts are rushing to upgrade, cut, or cover
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
06:22am, Wednesday, 15'th Jul 2026
Company Announcement Net sales of DARZALEX ® in the second quarter of 2026 totaled USD 4,207 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma
12:15pm, Tuesday, 07'th Jul 2026
AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, backed by phase III data showing strong efficacy.
Media ReleaseCOPENHAGEN, Denmark; July 6, 2026 TEPKINLY (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of follic
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenal
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity
12:31pm, Tuesday, 30'th Jun 2026
Genmab A/S – ADR (NASDAQ:GMAB) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 trial.
Genmab Shares Climb After Lymphoma Therapy Hits Goal in Trial
05:35am, Tuesday, 30'th Jun 2026
The Danish biotechnology company and partner AbbVie said a drug combination to treat lymphoma met the primary goal in a late-stage clinical trial.
Company Announcement Topline results from Phase 3 EPCORE ® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improveme
Capital Increase in Genmab as a Result of Employee Warrant Exercise
03:12pm, Tuesday, 16'th Jun 2026
Company Announcement COPENHAGEN, Denmark; June 16, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 185 shares as a consequence of the exercise of employee warrants. The increase
Major Shareholder Announcement
12:04pm, Monday, 15'th Jun 2026
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 15, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Market
[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously
